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Abstract
 
M11L, a novel 166–amino acid membrane-associated protein expressed by the poxvirus, myx-
oma virus, was previously found to modulate apoptosis after infection of rabbit leukocytes.
Furthermore, infection of rabbits with an M11L knockout virus unexpectedly produced lesions
with a profound proinflammatory phenotype. We show here that M11L is antiapoptotic when
expressed independently of other viral proteins, and is directed specifically to mitochondria by
a short COOH-terminal region that is necessary and sufficient for targeting. This targeting re-
gion consists of a hydrophobic domain flanked by basic amino acid residues, adjacent to a pos-
itively charged tail. M11L blocks staurosporine-induced apoptosis by preventing mitochondria
from undergoing a permeability transition, and the mitochondrial localization of this protein is
essential for this function. We show that M11L is specifically required to inhibit the apoptotic
response of monocytes/macrophages during virus infection, as cells of this lineage undergo ap-
optosis when infected with the M11L knockout virus. As monocyte apoptosis is uniquely
proinflammatory, we propose that this observation reconciles the paradoxical proapoptotic and
proinflammatory phenotypes of the M11L knockout virus. We suggest that apoptosis of tissue
macrophages represents an important antiviral defense, and that the inhibition of apoptosis by
viral proteins can be directed in a cell-specific fashion.
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Introduction
 
Virus infection of a host triggers numerous cellular defen-
sive responses designed to limit viral replication and con-
tain the infection. To ensure continued virion production
in the face of this immune response, viruses have, in turn,
developed strategies to counteract cellular defenses and
maintain a suitable environment for their own replication.
A key innate cellular response to infection is apoptosis (1–
3), and a growing number of viral antiapoptotic proteins
continue to be characterized (1, 2, 4–6).
 
In certain cases, the roles of these viral antiapoptotic
 
proteins have been defined. Some, including the viral Fas-
 
associated death domain–like IL-1
 
b
 
–converting enzyme
 
(FLICE) inhibitory proteins (vFLIPs),
 
1
 
 encoded by many
gammaherpesviruses as well as by the molluscum contagio-
sum poxvirus (2, 7), target the initial signal transduction
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Abbreviations used in this paper:
 
 CCCP, carbonyl cyanide 
 
m
 
-chlorophenyl
 
hydrazone; COX IV, cytochrome c oxidase subunit IV; DiOC
 
6
 
, 3,3
 
9
 
-
dihexyloxacarbocyanine iodide; FBS, fetal bovine serum; GFP, green
fluorescent protein; MOI, multiplicity of infection; TMRE, ethyl ester
of tetramethylrhodamine; TUNEL, terminal deoxynucleotidyl trans-
ferase–mediated dUTP-fluorescein nick end labeling; vFLIP, viral
FLICE inhibitory protein. 
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events leading to apoptosis. The vFLIPs specifically disrupt
signaling by the Fas/TNF family of death receptor proteins
by preventing complete assembly of the death-inducing
signaling complex on the cytoplasmic domains of these re-
ceptors after activation. Viruses have also devised strategies
to target the caspases, the family of apoptotic proteases that
play key roles as initiators and effectors of apoptotic events.
Viral proteins able to counteract the caspases include p35 of
baculovirus, the poxviral serpin CrmA/Spi2, and the E3-
14.7K protein of adenovirus (2, 5, 8). The baculovirus in-
hibitors of apoptosis proteins (IAPs) are another class of
proteins implicated in the regulation of caspase activation, a
function that may be linked to their ability to counter the
effects of the proapoptotic proteins RPR, GRIM, HID,
and DOOM in insect cells (9). Other viral proteins modu-
late the cell death checkpoint mediated by the Bcl-2 family
of apoptotic regulators. Viral proteins such as the Bcl-2 ho-
mologues encoded by the lymphotropic gammaherpesvi-
ruses, the E1B-19K protein of adenovirus, and the 5-HL
protein of African swine fever virus have sequence and/or
functional homology to cellular Bcl-2 proteins and are
able to abrogate the activity of the proapoptotic Bcl-2 fam-
ily members, in some cases by direct physical interaction (2,
5, 7).
Recent experimental findings have indicated a pivotal
role for mitochondria in the “decision to die” checkpoint
regulated by Bcl-2 proteins (10–13). In this context, Bcl-2
proteins are believed to regulate the mitochondrial perme-
ability transition (PT) pore and thereby control the release
of cytochrome c and other proteins from within mitochon-
dria into the cytoplasm. Once these proteins are able to in-
teract with cytoplasmic components, they become proapop-
totic and mediate the activation of key downstream
effectors such as caspase-3. Like their cellular counterparts,
certain viral Bcl-2 family members have been associated
with the mitochondrial checkpoint. In particular, stable ex-
pression of the herpesvirus saimiri Bcl-2 protein in Jurkat
lymphocytes has been shown to prevent loss of mitochon-
drial membrane potential, cytochrome c release, and cas-
pase-3 activation after ligation of the Fas receptor (14).
Recently, an antiapoptotic human cytomegalovirus pro-
tein, vMIA, has been described that has no homology to
other known proteins and localizes to mitochondria. This
protein inhibits mitochondrial changes typically associated
with apoptosis, such as the release of cytochrome c into the
cytoplasm and, significantly, binds the adenine nucleotide
carrier subunit of the permeability transition (PT) pore
(15).
 
 
 
The characterization of novel viral proteins such as
vMIA demonstrates how analysis of viral protein function
can provide valuable insight into normal cellular processes.
Several poxvirus-encoded proteins have been implicated
in regulating apoptotic cascades, but presently most of these
proteins have an undefined mechanism of action. Included
among the poxvirus apoptotic modulators are several pro-
teins encoded by myxoma virus (16, 17), a Leporipoxvirus
which is the causative agent of a lethal disease, myxomato-
sis, in the European or laboratory rabbit (18). Myxoma vi-
rus apoptotic modulators include M-T2, M-T4, M-T5,
 
and M11L, as revealed by the finding that expression of
these proteins is required during infection of RL-5 rabbit
lymphocytes to prevent apoptosis and allow efficient virus
replication (19–21).
M11L is a novel myxoma virus–encoded protein that
currently has no database homologues outside the poxvirus
family (22). It is 166 amino acids in length and has no dis-
tinct structural motifs apart from a hydrophobic stretch of
18 amino acids near the COOH terminus that constitutes a
putative transmembrane region. M11L plays an important
role in the virulence of myxoma virus during host infec-
tion. This was demonstrated during characterization of a
myxoma virus variant unable to express the M11L protein
as a result of a targeted gene disruption. In marked contrast
to the parental virus, which gives rise to the lethal symp-
toms of myxomatosis, the M11L deletion mutant elicited a
highly attenuated, nonlethal disease phenotype in labora-
tory rabbits. Despite its reduced virulence, however, the le-
sions produced by the M11L knockout virus were unusual,
and histological analysis revealed signs of vigorous inflam-
matory activity. The knockout virus was also shown to be
impaired in its ability to replicate in primary rabbit spleno-
cytes (23). The attributes of M11L suggested a model in
which this protein could act as a virulence factor by pre-
venting apoptosis of leukocytes during host infection,
thus compromising the effectiveness of cellular protective
mechanisms designed to limit viral propagation.
In this paper, we demonstrate that M11L is antiapoptotic
when expressed independently from other viral proteins.
Significantly, M11L localizes to mitochondria, and we pro-
vide evidence that the protection afforded by M11L influ-
ences the mitochondrial checkpoint. Finally, we show that
M11L is required to maintain the viability of primary rabbit
monocytes infected with myxoma virus and suggest a key
role for M11L linking the inhibition of apoptosis with in-
flammation suppression during infection.
 
Materials and Methods
 
Cells.
 
RL-5 rabbit CD4
 
1
 
 lymphocytes (National Institutes
of Health AIDS Reagent Program) and HeLa cells (American
Type Culture Collection) were maintained in RPMI medium
(GIBCO BRL) supplemented with 10% fetal bovine serum
(FBS; GIBCO BRL). Primary rabbit monocytes were cultured
in the same medium supplemented with 20% FBS. Rat2 fibro-
blasts, COS-7 monkey fibroblasts, and HepG2 human hepato-
cellular carcinoma cells (American Type Culture Collection)
were maintained in DMEM (GIBCO BRL) supplemented with
10% FBS. BGMK monkey kidney cells (obtained from Dr. S.
Dales, University of Western Ontario) were maintained in
DMEM supplemented with 10% newborn calf serum (GIBCO
BRL). All media contained 200 U/ml penicillin and 200 
 
m
 
g/ml
streptomycin.
 
Virus Infections.
 
Recombinant viruses used in this study have
been described previously. These include vMyxlac, a control
myxoma virus that produces M11L, vMyxM11L
 
2
 
 which fails to
produce M11L owing to a targeted gene disruption (23), and
vMyxM11L
 
R
 
, a revertant virus in which the gene disruption has
been repaired (20). A vaccinia virus construct that overexpresses
M11L, VVM11L (22), and a control vaccinia virus, VV601, were 
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also employed. Other myxoma virus constructs used in this study
included the M-T2 (24), M-T4 (19), and Serp-1 (25) targeted
disruption mutants. Cells were infected at a multiplicity of infec-
tion (MOI) of 10 as described (19).
 
Plasmid Constructs.
 
The 
 
M11L
 
 coding sequence was ampli-
fied by PCR using the primers 5
 
9
 
Eco (GCTAGAATTCAT-
GATGTCTCGTTTAAAGAC) or 5
 
9
 
Xho (GGATCTCGAG-
ATGATGTCTCGTTTAAAGAC) and 3
 
9
 
Sal (CGTAGTCG-
ACTAGGTCCCTCGGTACC), and cloned into the T-tailed
vector pT7blue (Novagen). For retrovirus-directed expression of
M11L, the gene was subcloned into the murine leukemia virus–
based vector pBabePuro (26) to produce the vector pBabe-
PuroM11L. To allow the expression of GFP-M11L, a fusion
protein consisting of green fluorescent protein (GFP) appended
to the NH
 
2
 
 terminus of M11L, the 
 
M11L
 
 coding sequence was
cloned into the GFP expression vector pS65T-C1 (Clontech)
encoding the S65T variant of GFP so that the 
 
M11L
 
 sequence
was inserted downstream of and in frame with the GFP coding
sequence. A mutated form of M11L was created using a PCR-
based approach. The 
 
M11L
 
 coding sequence was amplified using
the 5
 
9
 
Xho primer detailed above and a 3
 
9
 
 primer M11Lstop
(AACTGCCGCGGTTAGATAGACGGATCATTT) incorpo-
rating a stop codon in place of the codon specifying isoleucine at
position 143, the first amino acid of the hydrophobic region. A
restriction fragment containing the mutated codon was excised
from this amplified PCR product and used to replace the corre-
sponding fragment of the wild-type 
 
M11L 
 
gene. These con-
structs were subcloned into the pEGFP-C1 vector (Clontech) to
allow expression of the same M11L constructs appended to the
COOH terminus of the EGFP (enhanced) variant of GFP, which
has a higher fluorescence intensity. To identify a minimal mito-
chondrial targeting signal contained in M11L, a restriction frag-
ment containing the coding sequence for the last 25 amino acids
of the protein was cloned into pEGFP-C1. As a positive control,
the Bcl-2 coding sequence (provided by Dr. S. Farrow, Glaxo
Wellcome Research and Development, Stevenage, UK) was
cloned into pEGFP-C1 to allow expression of an EGFP–Bcl-2
chimeric protein. Correct construction of all GFP chimeras was
verified by DNA sequencing analysis.
 
Ectopic Expression of M11L.
 
Control pBabePuro and pBabe-
PuroM11L vectors were transiently transfected into BOSC 23
cells and packaged into ecotropic virus particles as described (27).
After infection of Rat2 fibroblasts, pooled clones of cells that had
stably incorporated the respective proviruses were selected on the
basis of ability to grow in the presence of 2.5 
 
m
 
g/ml puromycin,
and designated Rat2puro and Rat2M11L. Expression of the
M11L protein by Rat2M11L cells was verified by immunoblot
analysis (data not shown). Transient expression of GFP chimeric
proteins for flow cytometry was accomplished by transfecting
HeLa cells with GFP plasmid constructs using the Lipofectin Plus
reagent (GIBCO BRL) as described (28). Analysis was conducted
24 h after transfection.
 
Induction and Measurement of Apoptosis.
 
Apoptosis was in-
duced by addition of staurosporine (Sigma Chemical Co.) to the
cell culture medium at a final concentration of 2 
 
m
 
M. Apoptotic
cells were identified by measuring the characteristic elevation in
levels of nicked DNA using the previously described terminal
deoxynucleotidyl transferase–mediated dUTP-fluorescein nick
end labeling (TUNEL) reaction (19, 29).
 
Measurement of Caspase-3 Activation.
 
Rat2puro and Rat2-
M11L cells (10
 
6
 
) were incubated with 5 
 
m
 
M staurosporine for up
to 4 h. Caspase-3 activation was detected by SDS-PAGE and im-
munoblot analysis as described (30) using an antibody directed
 
against the large subunit of the active enzyme (provided by Dr.
D. Nicholson, Merck-Frosst Center for Therapeutic Research,
Montreal, Quebec, Canada).
 
Confocal Microscopy.
 
To study M11L localization in myxoma
virus–infected cells, BGMK cells grown on coverslips were
treated 20 h after infection with the mitochondrial-specific fluo-
rescent marker Mitotracker Red CXMRos (Molecular Probes) at
a final concentration of 30 ng/ml. Accumulation of the dye was
allowed to occur for 20 min at 37
 
8
 
C. The cells were fixed with
2% paraformaldehyde/PBS for 30 min at room temperature and
permeabilized for 2 min with cold 0.1% Triton X-100/0.1% so-
dium citrate buffer. Cells were then incubated for 20 min at
room temperature with a polyclonal rabbit anti-M11L antibody
(22) diluted 1:50 in PBS followed by incubation for 20 min at
room temperature with a secondary FITC-conjugated anti–rabbit
antibody (Jackson ImmunoResearch Laboratories) at a dilution of
1:200 in PBS. Coverslips were mounted using 50% PBS/50%
glycerol solution, and confocal images were obtained using an
LSM510 laser scanning confocal microscope mounted on a Zeiss
Axiovert 100M microscope equipped with a 63
 
3
 
 1.4 oil immer-
sion Plan-Apochromat objective. FITC excitation was induced
by illumination at 488 nm, and the fluorescent signal was col-
lected using a 505–530-nm band pass filter. Mitotracker Red flu-
orescence was induced by illumination at 543 nm and was de-
tected using a 560-nm long pass filter.
Images of live cells were obtained by growing cells in 3.5-cm-
diameter cell culture dishes modified so that a section of the base
was replaced by a glass No. 1 coverslip (Fisher Scientific). Par-
tially confluent monolayers of COS-7 or HeLa cells were each
transfected with 4 
 
m
 
g DNA using the Lipofectin reagent and Op-
tiMEM medium (GIBCO BRL) according to the manufacturer’s
specifications. The transfected cells were incubated for 24 h, and
mitochondria were stained with Mitotracker Red CXMRos
(Molecular Probes) by addition of the dye to the culture medium
at a concentration of 15 ng/ml. Cells were replenished with
RPMI medium lacking phenol red (GIBCO BRL) and examined
by confocal microscopy using the same filter settings described
above. Red and green signals were collected sequentially to elim-
inate bleed-through. Neutral density filters were set at levels of
80% or higher to minimize photobleaching.
 
Analysis of Protease Sensitivity.
 
HepG2 cells (5 
 
3 
 
10
 
5
 
) were
infected at an MOI of 10 with the M11L-overexpressing vaccinia
virus VVM11L, or with the control virus VV601 for 12 h. The
cells were harvested and resuspended in 200 
 
m
 
l digitonin lysis
buffer (75 mM NaCl, 1 mM NaH
 
2
 
PO
 
4
 
, 8 mM Na
 
2
 
HPO
 
4
 
, 250
mM sucrose, and 95 
 
m
 
g/ml digitonin) at 4
 
8
 
C for 5 min to permit
selective permeabilization of the plasma membrane without dis-
rupting intracellular membranes (31). Both samples were divided
into four aliquots of 50 
 
m
 
l each and centrifuged at 15,000 
 
g
 
 for 15
min at 4
 
8
 
C, and the supernatants were retained. The pellets were
resuspended in 50 
 
m
 
l digitonin lysis buffer. Duplicate samples
were then treated with the protease inhibitor PMSF (Sigma
Chemical Co.) at a final concentration of 1 mM immediately or
treated with 2.5 
 
m
 
g/
 
m
 
l proteinase K (Boehringer Mannheim) at
4
 
8
 
C for 20 min before the reaction was quenched by PMSF addi-
tion. One of the duplicate samples was then resuspended in SDS
sample buffer, and the whole cell lysate was used to detect cyto-
chrome c oxidase subunit IV (COX IV). The other sample was
used to immunoprecipitate M11L. This was achieved by dilution
of the sample to 1 ml in NP-40 lysis buffer (50 mM Tris-HCl,
pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 2
mM EDTA, and 1 mM PMSF) and agitation at 4
 
8
 
C for 30 min.
Insoluble material was pelleted at 4
 
8
 
C by centrifugation at 15,000 
 
g 
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for 10 min. The supernatant was removed, and 10 
 
m
 
l of rabbit
polyclonal antibody (22) was added. The samples were incubated
at 4
 
8
 
C with constant agitation for 2 h, and 20 
 
m
 
l of a 50% slurry
of protein A–Sepharose beads (Amersham Pharmacia Biotech)
was added before further incubation for 1 h. The beads were then
pelleted by low speed centrifugation, washed in lysis buffer, and
boiled in SDS sample buffer for 5 min. For COX IV and M11L
detection, proteins were separated by SDS-PAGE on a 15% gel
and electroblotted onto Immobilon-P membrane (Millipore).
COX IV was detected using a primary mouse mAb (Molecular
Probes) at a concentration of 0.4 
 
m
 
g/ml and a secondary anti–
mouse-horseradish peroxidase conjugate
 
 
 
(Bio-Rad) at 1:6,000
dilution followed by enhanced chemiluminescence detection
(ECL; Amersham Pharmacia Biotech). M11L was detected using
the primary rabbit polyclonal antibody at a dilution of 1:500 and a
secondary protein A–horseradish peroxidase conjugate (Pierce
Chemical Co.) at a dilution of 1:10,000 followed by ECL detec-
tion.
 
Measurement of Mitochondrial Membrane Potential in Cells Express-
ing M11L Constructs.
 
Rat2puro or Rat2M11L cells were cul-
tured in 12-well plates (5 
 
3 
 
10
 
5
 
 cells/well) and treated with 2
 
m
 
M staurosporine for 4 h. As the staurosporine stock was pre-
pared in DMSO, control cells were treated with an equivalent
amount of DMSO alone. Thereafter, the cells were stained with
the green fluorescent dye 3,3
 
9
 
dihexyloxacarbocyanine iodide
(DiOC
 
6
 
; Molecular Probes). The fluorescence intensity of this
dye has been found to correlate with the mitochondrial mem-
brane potential and provide an accurate measure of loss of this
potential during apoptosis (32). Cells were incubated with 0.5
nM DiOC
 
6
 
 at 37
 
8
 
C for 10 min, harvested with trypsin, and then
washed and resuspended in RPMI lacking phenol red (GIBCO
BRL). To verify that a decrease in the fluorescence signal inten-
sity did accompany a loss of mitochondrial membrane potential,
control cells were treated with the protonophore carbonyl cya-
nide 
 
m
 
-chlorophenyl hydrazone (CCCP; Molecular Probes),
which causes dissipation of the proton gradient across the mito-
chondria inner membrane (32). CCCP was added to the cell cul-
ture medium at a final concentration of 50 
 
m
 
M during and after
dye addition. Flow cytometric analysis was conducted using a
Becton Dickinson FACSCalibur™ flow cytometer equipped
with
 
 
 
an
 
 
 
argon ion laser with 15 mW of excitation at 488 nm.
Data were acquired at 10,000 cells per sample, and the fluorescent
signal due to excitation of DiOC
 
6
 
 at 488 nm was detected
through the FL1 channel equipped with a 530-nm filter (30-nm
band pass). Light scatter signals were acquired at linear gain, and
fluorescence signals were acquired at logarithmic gain.
HeLa cells transiently expressing GFP plasmid constructs were
treated with 2.5 
 
m
 
M staurosporine, and control samples were
treated with DMSO alone. Measurement of changes in mito-
chondrial membrane potential in this system was conducted using
the ethyl ester of tetramethylrhodamine (TMRE; Molecular
Probes), as the accumulation of this dye in the mitochondria of
HeLa cells correlates directly with the magnitude of the negative
mitochondrial membrane potential. In addition, this dye displays
no appreciable nonspecific binding, self-quenching, or cellular
toxicity (33, 34). TMRE was added to cells at a final concentra-
tion of 0.1 
 
m
 
M, and CCCP was added to a control sample. Flow
cytometric analysis to detect green fluorescence due to GFP and
orange fluorescence due to TMRE was conducted using a FACS-
Calibur™ instrument specified above. GFP fluorescence was col-
lected after a 530/30-nm band pass filter, and TMRE fluorescence
was acquired through a 585/42-nm band pass filter. Electronic flu-
orescence compensation was set to eliminate any spectral overlap
 
of the emitted signals. Data were acquired at 10,000 cells per sam-
ple with fluorescence signals at logarithmic gain. The percentage
of GFP-positive cells that were also TMRE-positive was then
calculated for each gated cell population.
 
Isolation, Infection, and Analysis of Primary Rabbit Monocytes.
 
For each experiment, heparinized blood was obtained by cardiac
puncture from a healthy New Zealand White laboratory rabbit
and subjected to Ficoll-Paque (Amersham Pharmacia Biotech)
density gradient separation. The buffy coat containing white
blood cells was collected, and cells were cultured in RPMI me-
dium containing 20% FBS for 4 h; the monocyte population was
enriched as a result of adherence to the plastic culture dish. The
adherent cells were detached from the plastic support using warm
1
 
3
 
 SSC (150 mM sodium chloride, 15 mM sodium citrate, pH
7.5) and infected with appropriate viruses at an MOI of 10. Typ-
ically, infection rates exceeded 70% as verified by staining with
X-gal (23). The infected cells were cultured in medium contain-
ing 20% FBS for 12 h, fixed in 2% paraformaldehyde/PBS, and
apoptotic cells were detected using the TUNEL reaction. The
monocyte population in each sample was identified by indirect
immunofluorescence by incubation with a mouse anti–rabbit
CD11b antibody (Spring Valley) at a dilution of 1:50 at room
temperature for 20 min, followed by incubation with a PE-con-
jugated F(ab
 
9
 
)
 
2
 
 goat anti–mouse secondary antibody (Dako) at a
dilution of 1:20 at room temperature for 20 min. Data were ac-
quired using a Becton Dickinson FACScan™ flow cytometer us-
ing the same settings described for the FACSCalibur™ instru-
ment. The fluorescein-dUTP signal from TUNEL-positive cells
and PE fluorescence from CD11b-positive cells was analyzed for
the gated cell population.
 
Results
 
The M11L Protein of Myxoma Virus Is Antiapoptotic.
 
In
view of the experimental findings that several different tar-
geted gene disruptions in the myxoma virus genome
yielded virus variants with proapoptotic phenotypes (19–
21), it followed that myxoma virus encodes more than one
protein able to directly modulate apoptotic cascades. First,
however, it was of interest to ascertain whether myxoma
virus infection provided cells with protection from exoge-
nous apoptotic stimuli in addition to the process of virus
infection itself. RL-5 rabbit T lymphocytes were mock-
infected or infected with myxoma virus (vMyxlac), and 12 h
after infection were treated with the apoptosis inducer
staurosporine at a concentration of 2 
 
m
 
M for up to 4 h.
Apoptotic cells were identified by measuring the charac-
teristic elevation in the levels of nicked DNA using
TUNEL analysis. After staurosporine treatment, the per-
centage of TUNEL-positive (apoptotic) cells was found to
be substantially higher in the mock-infected cell popula-
tion than was the case with infected cells (Fig. 1 A). Thus,
myxoma virus infection counteracts the proapoptotic ef-
fects of staurosporine.
In contrast to parental myxoma virus, the M11L knock-
out virus has a distinct proapoptotic phenotype when in-
fecting RL-5 cells (20).
 
 
 
This finding suggested that, during
the normal course of myxoma virus infection, M11L is one
of the factors that provides an antiapoptotic function (16).
Therefore, we investigated the possibility that M11L has 
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protective, antiapoptotic properties that are able to extend
beyond the context of virus infection. To achieve this, we
expressed M11L in Rat2 fibroblasts using a retrovirus-based
approach. The ability of staurosporine to induce apoptosis
in M11L-expressing Rat2M11L cells and control Rat2puro
cells, transfected with empty vector alone, was monitored
by measuring DNA fragmentation using the TUNEL assay.
Whereas 2 
 
m
 
M staurosporine treatment over a 5-h duration
produced a steady increase in the levels of TUNEL-positive
Rat2puro cells, the levels of TUNEL-positive Rat2M11L
cells were considerably reduced under the same conditions,
indicating that M11L expression alone confers resistance to
staurosporine-induced apoptosis (Fig. 1 B). This result pro-
vided the first evidence that M11L is antiapoptotic when
expressed independently of other myxoma virus proteins
and is able to function in cells derived from a species other
than rabbit.
To confirm the idea that M11L directly impacts an
apoptotic cascade, we asked whether M11L interferes with
end-stage
 
 
 
apoptotic processes, such as the cleavage and ac-
tivation of the effector caspase, caspase-3. To address this
question, we monitored caspase-3 processing in Rat2puro
and Rat2M11L cells by immunoblot analysis using an anti-
body directed against the large subunit of the active caspase.
Treatment of Rat2puro cells with 5 
 
m
 
M staurosporine over
a duration of 4 h resulted in activation of caspase-3 as re-
vealed by reduction in the amount of the 32-kD proen-
zyme and appearance of the p19 cleavage product, a com-
 
ponent of the active enzyme (Fig. 1 C, top). In contrast,
caspase-3 activation in Rat2M11L cells after the same treat-
ment was substantially reduced (Fig. 1 C, bottom), with
only a low level of activation being apparent after 4-h treat-
ment (compare lane 4, top and bottom). In additional ex-
periments (data not shown), M11L expression in Rat2 fi-
broblasts was found to inhibit staurosporine-induced
cleavage of poly(ADP-ribose) polymerase, a substrate of ef-
fector caspases such as caspase-3 (35). These findings sug-
gest that M11L impedes apoptotic signaling events up-
stream of caspase-3 activation.
 
M11L Localizes to Mitochondria in Infected Cells.
 
Our
studies demonstrated that M11L is antiapoptotic, but data-
base searches failed to identify similarities between M11L
and any other protein of known function. However, se-
quence analysis of M11L revealed the presence of a
COOH-terminal putative transmembrane domain. This
observation prompted us to investigate the subcellular lo-
calization of M11L during myxoma virus infection. BGMK
cells were infected with M11L-expressing myxoma virus
(vMyxlac) or the M11L knockout virus (vMyxM11L
 
2
 
),
and 20 h after infection, M11L was visualized by indirect
immunofluorescence and confocal microscopy. As ex-
pected, M11L was detected in vMyxlac-infected cells (Fig.
2 A, panel a) and not in cells infected by the knockout virus
(Fig. 2 A, panel d). In addition, M11L was observed to
have a punctate, cytoplasmic distribution reminiscent of
mitochondrial targeting. To determine whether M11L did,
Figure 1. M11L is antiapoptotic. (A)
Mock- or myxoma virus (vMyxlac)-infected
RL-5 rabbit T lymphocytes were treated
with 2 mM staurosporine, and apoptosis
was measured using TUNEL analysis at the
time intervals indicated. Levels of TUNEL-
positive (apoptotic) cells were elevated in
the mock-infected cell population com-
pared with myxoma virus–infected cells,
indicating that virus infection protects RL-5
cells from apoptosis after staurosporine
treatment. (B) Rat2 fibroblasts ectopically
expressing M11L (Rat2M11L) or contain-
ing the vector alone (Rat2puro) were
treated with 2 mM staurosporine, and apop-
tosis was monitored at the times indicated
using TUNEL analysis. Apoptosis levels
were elevated in Rat2puro cells compared
with Rat2M11L cells, indicating that M11L
expression alone protects Rat2 cells from
the proapoptotic effects of staurosporine.
(C) Rat2puro and Rat2M11L cells were
treated with 5 mM staurosporine for the
times indicated, and caspase-3 was detected
in whole cell lysates by SDS-PAGE and
immunoblot analysis using an antibody di-
rected against the large subunit of the active
caspase. Cleavage of the 32-kD procaspase-3
to produce the detectable 19-kD compo-
nent of the active caspase was observed in
Rat2puro cells (top) but was considerably
reduced in Rat2M11L cells (bottom).
Hence, M11L expression impedes caspase-3
activation after treatment of Rat2 cells with
staurosporine.1492 Antiapoptotic Myxoma Virus Protein M11L
indeed, localize to mitochondria, cells were treated with
the mitochondrion-specific dye Mitotracker Red (Fig. 2 A,
panels b and e). When the fluorescent signals due to M11L
and Mitotracker Red were superimposed, a uniform yellow
image was produced, indicating that the two signals were
coincident (Fig. 2 A, panel c). No such signal was observed
in the case of cells infected with the knockout virus (Fig. 2
A, panel f). This result provides evidence that, within myx-
oma virus–infected cells, intracellular M11L localizes pre-
dominantly to mitochondria.
To investigate the topology of M11L within mitochon-
dria, we conducted experiments to determine whether
M11L is proteinase K sensitive. For these experiments, we
used the human hepatocyte-derived HepG2 cell line, as
these cells contain a high proportion of mitochondria. Dig-
itonin extracts of HepG2 cells were separated into pellet
and supernatant fractions after infection for 12 h with the
M11L-overexpressing virus vector VVM11L or the control
virus VV601 (which does not express M11L). Samples
were treated with proteinase K or left untreated before im-
munoblot analysis of M11L or COX IV, a protein that re-
sides in the inner mitochondrial membrane. As can be seen
from Fig. 2 B (top), the majority of the M11L protein is
present in the pellet fraction (lanes 1 and 5), which contains
membrane-associated components. A small proportion of
M11L can be detected in the soluble fraction (lanes 3 and
7), as would be expected for a protein produced by a cyto-
plasmic virus. M11L protein was not present in cells in-
fected with the control virus, as expected (lanes 2, 4, 6, and
8). COX IV was only detected in the pellet fractions (Fig. 2
B, bottom, lanes 1, 2, 5, and 6). However, when the pro-
tease sensitivity of M11L was assessed, it was evident that
M11L present in the pellet fraction was proteinase K sensi-
tive (Fig. 2 B, top, lane 1). M11L present in the supernatant
fraction was also protease sensitive, as revealed after overex-
posure of the immunoblot (data not shown). In contrast,
COX IV, present in the pellet fraction, was protease resis-
tant (Fig. 2 B, bottom, lanes 1 and 2). These data provide
evidence that M11L, although associated with mitochon-
dria, is exposed on the cytoplasmic face of the organelle.
M11L Expressed in Uninfected Cells Localizes to Mitochon-
dria and Contains a COOH-terminal Mitochondrial Targeting
Signal. We next sought to determine the spatial distribu-
tion of M11L in live, transfected cells. A chimeric form of
M11L bearing an NH2-terminal GFP tag was expressed in
both COS-7 and HeLa cells. As was the case for M11L de-
tected in virus-infected BGMK cells, GFP-tagged M11L
displayed a punctate cytoplasmic distribution both in COS-7
cells (Fig. 3 d) and HeLa cells (data not shown) which was
suggestive of association with intracellular membranes.
Upon comparison of the GFP-M11L signal fluorescence
pattern with that of Mitotracker Red in the same cells (Fig.
3 e), the two signals were found to be coincident (Fig. 3 f),
indicating that GFP-M11L localizes to mitochondria. In
contrast, GFP alone produced a diffuse signal throughout
COS-7 cells (Fig. 3, a and c), reflecting its lack of intracel-
lular targeting and lack of correspondence with Mitotracker
Red staining (Fig. 3 b). These experiments therefore show
that a GFP tag, when added to the NH2 terminus of M11L,
does not alter the mitochondrial localization of the protein,
and that this localization is consistent in cells having differ-
ent species of origin.
Since the COOH-terminal 24 amino acids of M11L in-
clude a stretch of 18 amino acids that constitute a putative
Figure 2. M11L localizes to mitochondria in infected cells. (A) BGMK cells infected for 20 h with M11L-expressing myxoma virus (vMyxlac) or the
M11L knockout virus (vMyxM11L2) were treated with Mitotracker Red to identify mitochondria, and M11L was detected by indirect immunofluores-
cence. Cells were visualized by confocal microscopy. As expected, M11L was detected in cells infected with vMyxlac (a) but not in cells infected with the
M11L knockout virus (d), and Mitotracker Red produced punctate mitochondrial staining (b and e). Superimposed Mitotracker Red and M11L signals
(c) yielded a yellow image, indicating that M11L localizes to mitochondria. This was not observed in cells infected with the knockout virus (f). Bar, 10
nm. (B) The proteinase K (PK) sensitivity of the 18-kD M11L (top) or 17-kD COX IV (bottom) proteins was assessed. Digitonin lysates of HepG2 cells
infected with M11L-expressing VVM11L or the control virus VV601 (CNTL) were prepared 12 h after infection. Pellet (lanes 1, 2, 5, and 6) and super-
natant (sup; lanes 3, 4, 7, and 8) fractions were isolated. Samples were subjected to proteinase K treatment for 20 min (PK 20 min; lanes 1–4) or left un-
treated (PK 0 min; lanes 5–8), and M11L or COX IV were detected by SDS-PAGE and immunoblotting. M11L (top) but not COX IV (bottom) in the
pellet fraction (lane 1) was sensitive to proteinase K treatment, indicating that although M11L is membrane associated, it is orientated towards the cytosol.1493 Everett et al.
transmembrane domain, we wished to determine whether
this domain was important for targeting. To address this
question, the localization of a GFP-tagged, truncated form
of M11L lacking the COOH-terminal 24 amino acids was
investigated. Interestingly, this truncated form of M11L
was distributed diffusely throughout the cytoplasm and nu-
cleus in COS-7 cells (Fig. 3, g and i) and showed no corre-
spondence with the staining pattern due to Mitotracker
Red (Fig. 3 h). The same result was obtained using HeLa
cells (data not shown). This shows that the COOH-termi-
nal 24 amino acids are necessary for M11L targeting to mi-
tochondria, and removal of this domain, which includes
the putative transmembrane region and short 6–amino acid
positively charged tail, prevents mitochondrial localization.
We next sought to determine whether the 25–amino
acid COOH-terminal region of M11L alone was sufficient
for mitochondrial targeting. The coding sequence for this
minimal region (designated mt, Fig. 4) was appended to
GFP and was found to direct GFP to punctate cytoplasmic
structures in both COS-7 (Fig. 4 a) and HeLa (Fig. 4 d)
Figure 3. GFP-tagged M11L localizes to mito-
chondria. COS-7 cells expressing GFP alone (a),
M11L bearing an NH2-terminal GFP tag (d), or a
GFP-tagged, truncated form of M11L (GFP-
M11Lstop) lacking the last 24 amino acids includ-
ing the hydrophobic region (g) were visualized by
confocal microscopy. Mitochondria were identified
by Mitotracker Red staining (b, e, and h). When
the Mitotracker Red fluorescence signal was
merged with that of GFP-M11L, a yellow image
was produced (f), indicating that GFP-M11L local-
izes to mitochondria in live, transfected cells. In
contrast, no colocalization was observed in the case
of GFP alone (c) or truncated M11L (i). Failure of
truncated M11L to localize to mitochondria indi-
cates that the last 24 amino acids are necessary for
targeting. Bar, 10 nm.
Figure 4. M11L contains a COOH-ter-
minal mitochondrial targeting signal. COS-7
or HeLa cells expressing GFP-mt, a con-
struct consisting of GFP tagged with the
COOH-terminal 25 amino acids of M11L
(mt) containing the putative transmembrane
domain (underlined), were visualized by
confocal microscopy. The distribution of
the GFP-mt (a and d) and Mitotracker red
(b and e) was found to be coincident (c and
f). Hence, the COOH-terminal 25 amino
acids of M11L are sufficient for mitochon-
drial targeting. Bars, 10 nm.1494 Antiapoptotic Myxoma Virus Protein M11L
cells. When the distribution of this fluorescent signal was
compared with that of Mitotracker Red (Fig. 4, b and e) in
the same cells, the two signals were found to be coincident
(Fig. 4, c and f). Hence, the COOH-terminal 25 amino ac-
ids of M11L comprise a signal that is sufficient for mito-
chondrial targeting. This targeting motif includes an 18–
amino acid putative transmembrane domain flanked by
positively charged lysine residues adjacent to a short 6–amino
acid COOH-terminal tail with a net positive charge
(Fig. 5). A truncated form of this sequence consisting of
only the last 19 amino acids of M11L failed to localize GFP
to mitochondria (data not shown), indicating the require-
ment for a hydrophobic stretch sufficiently long to form a
transmembrane segment within the targeting signal. The
M11L COOH-terminal targeting signal conforms to a
newly described consensus for directing proteins to mito-
chondria. This consensus consists of a hydrophobic region
flanked by positively charged residues adjacent to a short,
positively charged tail and was initially identified in vesicle-
associated membrane protein 1B (VAMP-1B), monoamine
oxidase A and B, and Bcl-2 (36). We found this consensus
to be additionally present in diverse Bcl-2 family members
(Fig. 5).
M11L Prevents Mitochondria from Undergoing a Permeability
Transition after Apoptosis Induction. Since M11L inhibits
apoptosis and localizes to mitochondria, it was of interest to
determine whether M11L could function by protecting
mitochondria from apoptotic changes, notably a permeabil-
ity transition revealed by loss of electrical potential differ-
ence across the inner membrane. The mitochondrial mem-
brane potential in Rat2puro and Rat2M11L cells was
measured as a function of DiOC6 fluorescence in the pres-
ence or absence of staurosporine treatment. Representative
results from one of three experiments shown in Fig. 6 A re-
veal that the mitochondria of control cells from both cell
lines stained brightly (Fig. 6 A, panels a and c). Fluores-
cence was diminished in the presence of the protonophore
CCCP, an uncoupler of the electron transport chain that
induces collapse of the mitochondrial inner membrane po-
tential (Fig. 6 A, panel a insert). However, when subjected
to the proapoptotic effects of staurosporine, mitochondria
in Rat2puro cells were found to be considerably more sen-
sitive to loss of membrane potential than were Rat2M11L
cells (Fig. 6 A, panels b and d). These results indicate that
M11L can protect mitochondria from undergoing a perme-
ability transition after receipt of an apoptotic signal induced
by staurosporine.
Similarly, we investigated the ability of transiently ex-
pressed GFP constructs to protect HeLa cells from loss of
mitochondrial membrane potential after staurosporine
treatment. TMRE was used to detect mitochondrial
changes in this series of experiments because, like DiOC6,
it displays decreased fluorescence intensity as mitochondrial
membrane potential diminishes but it emits a signal in the
orange spectral range and therefore does not interfere with
GFP fluorescence. TMRE has been successfully used to
monitor mitochondrial function in HeLa cells by confocal
microscopy (33) and, in this study, was also found to be
suitable for flow cytometric analysis, as is the related methyl
ester TMRM (32). The percentage of cells expressing GFP
constructs that were also TMRE-positive was determined
in control and staurosporine-treated cells. The reduction in
the percentage of TMRE-positive cells after staurosporine
treatment was then calculated. The average results for two
separate experiments are graphically represented in Fig. 6
B. As shown by this figure, expression of GFP alone, GFP
targeted to mitochondria (GFP-mt), and the nontargeted
GFP-M11Lstop truncation mutant all failed to prevent a
loss of TMRE fluorescence. This suggests that these con-
structs cannot protect mitochondria from undergoing a
loss of membrane potential after staurosporine treatment.
Treatment of GFP-expressing cells with CCCP also in-
duced a marked loss of TMRE fluorescence. In contrast,
expression of the GFP-M11L chimera and the positive
Figure 5. The M11L mitochondrial targeting signal
belongs to a consensus found in other proteins. Pro-
posed COOH-terminal consensus for targeting Bcl-2
family members to the mitochondrial outer membrane.
The COOH-terminal sequences shown include those
of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-
XL, Boo/Diva, and CED-9, the viral antiapoptotic
proteins M11L, BHRF-1, and KSbcl-2, as well as the
proapoptotic proteins Nip3 and Nix. aa, amino acid.1495 Everett et al.
control GFP–Bcl-2 construct resulted in TMRE fluores-
cence being retained in HeLa cells after the same treatment.
This indicates that M11L, like Bcl-2, can protect mito-
chondria in HeLa cells from undergoing a permeability
transition induced by the proapoptotic effects of staurospo-
rine. This property is dependent on M11L being correctly
localized to mitochondria.
M11L Is Required to Prevent Apoptosis during Infection of
Primary Rabbit Monocytes. On the basis of the experimen-
tal findings described in this paper, it would be predicted
that infection of rabbit leukocytes by the M11L knockout
virus would result in elevated levels of apoptosis in these
cells. Apoptosis is normally an immunologically silent event
(37), and therefore the strongly proinflammatory disease
phenotype elicited in rabbits infected with the knockout
virus is a seemingly conflicting observation. However, it
has been reported that monocyte apoptosis has the unusual
property of promoting inflammation (37, 38). Therefore,
we decided to test whether infection of monocytes with
the M11L knockout virus was able to induce apoptosis in
these cells, a situation that could explain the proinflamma-
tory phenotype of this virus.
Primary rabbit monocytes were isolated from peripheral
rabbit blood and infected with several myxoma virus con-
structs. After 12 h of infection, apoptotic cells were de-
tected by means of the TUNEL reaction, and cells of the
monocyte lineage were identified by the presence of the
CD11b surface marker. Populations of dual-positive cells
representing apoptotic monocytes were quantitated by flow
Figure 6. M11L prevents the
mitochondrial permeability tran-
sition. (A) Rat2puro (top) or
Rat2M11L (bottom) cells were
maintained as controls or treated
with staurosporine for 4 h and
stained with the fluorescent dye
DiOC6 to obtain a measure of
the mitochondrial membrane
potential. Representative results
of one of three separate experi-
ments are shown. Control cells
(a and c) displayed intense stain-
ing with the dye, indicating nor-
mal mitochondrial function. The
protonophore CCCP markedly
attenuated the fluorescent signal,
as expected (a, insert). A similar
reduction in the fluorescent sig-
nal was seen in Rat2puro cells
after apoptosis induction by stau-
rosporine (b). In contrast, signal
intensity and, therefore, mito-
chondrial function was retained
in Rat2M11L cells after the same
treatment (d). This shows that
M11L plays a role in preserving mitochondrial function after apoptosis induction. (B) HeLa cells were transiently transfected to allow expression of GFP,
mitochondria-targeted GFP (GFP-mt), or the fusion proteins GFP-M11L, GFP-M11Lstop, or GFP–Bcl-2. The percentage of GFP-expressing cells that
also displayed TMRE fluorescence was determined with or without staurosporine treatment. The reduction in the percentage of TMRE-positive cells af-
ter staurosporine treatment is represented here graphically and is the average of two separate experiments. The results show that a large percentage of cells
expressing GFP, GFP-mt, and the GFP-M11Lstop chimera (which is not localized to mitochondria) failed to retain TMRE fluorescence after staurospo-
rine treatment. CCCP also produced a loss of TMRE fluorescence in GFP-expressing cells, as expected. In contrast, GFP-M11L and GFP–Bcl-2 ex-
pressing cells maintained TMRE fluorescence after staurosporine treatment. This indicates that M11L, like Bcl-2, can protect the mitochondria of HeLa
cells from undergoing loss of membrane potential after apoptosis induction.
Figure 7. M11L is required to prevent apoptosis during myxoma virus
infection of primary rabbit monocytes. Primary rabbit monocytes were
infected with the M11L knockout virus (vMyxM11L2), a revertant of
this knockout virus (vMyxM11LR), control vMyxlac, or three other
myxoma virus constructs with targeted gene disruptions (vMyxT22,
vMyxT42, and vMyxSerp2). Apoptosis was measured by TUNEL analy-
sis (horizontal axis), and the CD11b-positive cells of monocyte origin
were identified by indirect immunofluorescence (vertical axis). Apoptotic
monocytes are represented in the second quadrant (percentage of total
cells shown). Apoptosis levels were elevated in cells infected with the
M11L knockout virus (vMyxM11L2) but not in cells infected with the
other virus variants, all of which express M11L. The data shown are rep-
resentative of four separate experiments and demonstrate a distinct role
for M11L in preventing apoptosis of infected monocytes.1496 Antiapoptotic Myxoma Virus Protein M11L
cytometry. Fig. 7 shows representative results from one of
four separate experiments and reveals that only the M11L
knockout virus induced notable levels of apoptosis in pri-
mary rabbit monocytes. In contrast, when monocytes were
infected with virus expressing M11L, including the control
vMyxlac virus, the M11L revertant virus, and myxoma vi-
rus constructs with other targeted gene disruptions, no ele-
vation in levels of apoptosis was observed. This finding is of
interest, as the M11L, M-T2, and M-T4 proteins are all re-
quired to prevent apoptosis during infection of the RL-5
lymphocytes, and disruption of any one of these genes pro-
duces a virus with a proapoptotic phenotype in this cell
line. In contrast, there appears to be a unique requirement
for M11L production during primary rabbit monocyte in-
fection. Virus constructs unable to produce either the
M-T2 or M-T4 protein, but still able to produce M11L, do
not have a proapoptotic phenotype in primary monocytes.
This result identifies a cell lineage where M11L production
is functionally significant in preventing apoptosis during in-
fection, and provides an explanation for the seemingly con-
flicting observations that the M11L knockout virus induces
apoptosis but also produces lesions with extensive infiltra-
tions of inflammatory cells in infected animals.
Discussion
The unique role of M11L in the virulence of myxoma
virus was indicated by two previous experimental observa-
tions. First, in contrast to control virus, an M11L knockout
myxoma virus elicited a markedly attenuated disease phe-
notype associated with unusual tumor-like lesions contain-
ing large numbers of infiltrating inflammatory cells (23).
Second, M11L was identified as a factor required to pre-
vent apoptosis during myxoma virus infection of RL-5
lymphocytes in vitro (20). These observations suggested a
model in which M11L acts as a virulence factor by virtue of
its ability to prevent infected leukocytes from initiating a
protective apoptotic response, thereby promoting viral rep-
lication.
These results suggested that M11L exerts a host cell–pro-
tective effect when the process of infection itself serves as
the apoptotic trigger. In this paper, we show for the first
time that M11L, when expressed independently from other
viral proteins, can protect these cells from the proapoptotic
effects of another inducer, namely staurosporine. The find-
ing that M11L can prevent caspase-3 activation and
poly(ADP-ribose) polymerase cleavage suggests that this
protein has a direct effect on a strategic step in an apoptotic
cascade upstream of caspase-3.
In this study, we investigated the intracellular localiza-
tion of M11L and demonstrated that this protein is prima-
rily targeted to mitochondria. A previous study (22) based
on indirect immunofluorescence analysis of nonpermeabi-
lized cells revealed that M11L can be detected on the sur-
face of infected cells. However, we have shown that surface
M11L probably represents only a minor proportion of
the total amount of protein produced in myxoma virus–
infected cells. The current study used the wild-type protein
expressed in the context of myxoma virus infection as well
as a plasmid-encoded GFP-M11L chimera visualized in
live, transfected cells to investigate the protein’s intracellu-
lar localization. We demonstrated that the majority of the
M11L protein within cells is targeted to mitochondria and
remains accessible to proteinase K digestion. This indicates
that M11L is associated with the outer mitochondrial
membrane and is oriented towards the cytoplasm. Hence,
M11L has an intracellular distribution similar to many Bcl-
2–like antiapoptotic proteins of both cellular and viral ori-
gin (11, 13). M11L contains a signal within the COOH-
terminal 25 amino acids that is necessary and sufficient for
mitochondrial targeting. This mitochondrial COOH-ter-
minal targeting signal conforms to a newly proposed con-
sensus domain which takes the form of a hydrophobic re-
gion flanked by positively charged residues adjacent to a
positively charged tail (36). Interestingly, COOH-terminal
targeting motifs responsible for directing other proteins in-
volved in apoptosis to the outer mitochondrial membrane
are also found to conform to this consensus (Fig. 5). In-
cluded in this category are Bcl-2 (31, 39), Bcl-XL (40),
BHRF-1 (41), Nip3 (41, 42), and Nix (43). This motif is
also present in the Bcl-2 family members Boo/Diva (44,
45), CED-9 (46), and KSbcl-2 from human herpesvirus 8
(47), although the intracellular localization of these proteins
and/or the precise role of this motif in targeting are un-
known at present.
We have shown that M11L prevents mitochondria from
undergoing a permeability transition after initiation of an
apoptotic signal by staurosporine. We demonstrated this
both in Rat2 cells stably expressing M11L and in HeLa
cells transiently transfected with a GFP-M11L construct.
Although there are pitfalls associated with the use of fluo-
rescent dyes for monitoring mitochondrial function (48,
49), we obtained the same result using two different fluo-
rescent probes in the two systems, supporting the conclu-
sion that M11L protects mitochondria from apoptotic
changes. In addition, the correct localization of M11L to
mitochondria appears to be essential for this function. It is
therefore likely that M11L acts as a viral survival effector by
preventing amplification of apoptotic cascades that proceed
via the mitochondrial pathway. Two other viral antiapop-
totic proteins, herpesvirus saimiri Bcl-2 and human CMV
vMIA, both expressed by herpesviruses, are similarly im-
portant for preservation of mitochondrial function after ex-
posure to apoptosis-inducing agents (14, 15). In the case of
myxoma virus and CMV, this function is also required to
sustain viral replication (15, 23).
To investigate the apparently contradictory observation
that the loss of M11L function results in the induction of
both apoptosis and a massive inflammatory response in in-
fected rabbits, we tested the ability of the M11L knockout
virus, as well as various other deletion mutant viruses, to
induce apoptosis during infection of primary rabbit mono-
cytes. Whereas a number of these myxoma virus deletion
mutants induce apoptosis in the RL-5 lymphocyte cell line,
only the M11L knockout virus elicited an apoptotic re-
sponse in primary rabbit monocytes. This indicates that ex-1497 Everett et al.
pression of M11L might be particularly important in allow-
ing myxoma virus to productively infect cells of the
monocyte/macrophage lineage, and is interesting in view
of the long-recognized importance of macrophages of the
reticulo-endothelial system in the development of myx-
omatosis (50). Elevated levels of apoptosis in tissues in-
fected by the knockout virus would not be anticipated in
association with signs of an increased inflammatory re-
sponse except in the unusual situation of apoptosis in cells
of the monocyte/macrophage lineage. This proinflamma-
tory effect could be attributed to a variety of causes. Mono-
cyte apoptosis has been shown to result in the processing
and release of the inflammatory cytokine IL-1b (38). In ad-
dition, monocyte-derived macrophages are responsible for
limiting the inflammatory effects of activated neutrophils
and other granulocytes. Hence, depletion of the monocyte
population could impair the normal regulatory processes of
the immune system, which are designed to contain the po-
tentially dangerous effects of uncontrolled inflammation
(37).
In conclusion, we show that M11L is an antiapoptotic
protein that localizes to the exterior of mitochondria by
means of a 25–amino acid COOH-terminal targeting motif
and protects this organelle from changes associated with ap-
optosis induction. M11L may be particularly important for
circumventing an apoptotic response in monocytes/mac-
rophages that infiltrate into lesions during myxoma virus
infection of rabbits. It will now be of interest to investigate
the role of M11L in protecting cells from additional apop-
totic inducers and to ascertain in more detail the role of this
protein in modulating mitochondrial function.
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